GlobeNewswire

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Share

Trial of CD22-targeting antibody drug conjugate being led by The University of Texas MD Anderson Cancer Center

LAUSANNE, Switzerland, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patients have been dosed in a Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-602 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The trial is being led by The University of Texas MD Anderson Cancer Center. 

ADCT-602 is an ADC that incorporates a pyrrolobenzodiazepine (PBD) drug linker and targets CD22, which is a clinically validated ADC target. Preclinical studies have demonstrated that ADCT-602 has significant anti-tumor activity in a number of animal models. 

Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia, and Nitin Jain, MD, Associate Professor in the Department of Leukemia, at MD Anderson, are leading the Phase I/II clinical trial of ADCT-602. The open-label trial will enroll up to 65 patients.

Dr. Kantarjian said, “There is a significant unmet need for new treatment options for adult patients with B-cell ALL who have not responded to initial treatment or whose cancer has returned after treatment. We are excited to evaluate the safety and anti-tumor activity of a CD22-targeted ADC in these patients.”

Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President at ADC Therapeutics, said, “We are delighted to be partnered with MD Anderson on this important clinical trial in adult patients with relapsed or refractory B-cell ALL, who have limited therapeutic options and for whom the prognosis is typically poor. We are hopeful that the response rates seen in our ADCT-402 and ADCT-301 lymphoma clinical trials can be replicated in the ALL patient population with ADCT-602, and that our growing portfolio of hematology-focused ADCs targeting CD19, CD25 and now CD22 can make a positive impact on patient outcomes.” 

For more information about this clinical trial, please visit www.clinicaltrials.gov (identifier NCT03698552).

About ADCT-602

ADCT-602 is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD22 conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD22-expresing cell, ADCT-602 is internalized into the cell where enzymes release the PBD-based warhead. CD22 is an attractive and clinically validated ADC target. CD22 is highly expressed on most malignant B-cells, including expression in greater than 90% of patients with B-cell acute lymphoblastic leukemia.

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has multiple PBD-based ADCs in ongoing clinical trials in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.

Investors Contact
Dr. Chris Martin
Chief Executive Officer
Chris.martin@adctherapeutics.com Tel.: +41 (0) 21 653 0200
  EU Media Contact
Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch Tel: +41 (0) 43 268 3231 
  USA Media Contact
Tony Plohoros
6 Degrees
tplohoros@6degreespr.com Tel.: +1 908-591-2839

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 201916.7.2019 22:00:00 CESTPress release

LYON, France and CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: Appointment of Jean-Paul KRESS as director; he was subsequently appointed to the position of Chairman of the Board of Directors; Renewal of the term of office of each of the following as a member of the Board of Directors: o Gil BEYEN; o Luc DOCHEZ; o Philippe ARCHINARD; o Galenos, represented by Sven ANDREASSON; Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2018 and quietus of directors; Allocation of the financial year's results; Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; Approval of the regulations of the share subscription and/or purchase

LGC Capital Ltd. Announces Change in Financial Year-End16.7.2019 18:30:00 CESTPress release

MONTRÉAL, July 16, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) wishes to announce that it is changing its financial year-end to December 31 from its current year-end of September 30. As a result, LGC will file an additional interim report as at September 30, 2019 and will report audited financial results for a 15-month transition year from October 1, 2018 to December 31, 2019 (with a comparative of the 12 months ended September 30, 2018). Afterwards, LGC will revert to a customary reporting calendar based on a December 31 year-end, with fiscal quarters ending on the last day of March, June, September and December each year. LGC believes this change of financial year-end will allow it to complete the audit requirements of its investee companies with greater efficiency and will be useful to consolidate other companies in the future. The notice for the change in financial year-end required under Regulation 51-102 respecting Continuous Disclosure Obligations will b

UPDATE -- OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:53:00 CESTPress release

First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers Monetize Customer Relationships SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to addres

OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:00:00 CESTPress release

First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to address the complex customer identific

Agreement with Eurekahedge Expands eVestment’s Hedge Fund Data Offering16.7.2019 14:00:00 CESTPress release

ATLANTA, July 16, 2019 (GLOBE NEWSWIRE) -- eVestment, a global leader in institutional investment data and analytics, today announced an agreement with Eurekahedge to offer Eurekahedge fund data and indices to clients of eVestment’s suite of Analytics solutions. eVestment Analytics clients will now have access to Eurekahedge’s global hedge fund data and indices, which cover over 30,000 hedge funds and funds of hedge funds spanning North American, European, Asian, Latin American and emerging markets. This expansion of data capabilities on the eVestment platform furthers eVestment’s focus on providing the most comprehensive institutional investment data to clients around the world across a wide variety of asset classes, including traditional investment strategies, hedge funds, funds of hedge funds and private markets investment opportunities. “Our clients need the most comprehensive data available to make the best decisions,” said eVestment Global Head of Insights John Molesphini. “Addin

ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CESTPress release

Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be